Cancer is a disease caused by the accumulation of genetic and epigenetic changes in two
types of genes: tumor suppressor genes (TSGs) and proto-oncogenes. Extensive research …

Triple-negative breast cancer (TNBC) is defined by a lack of expression of both estrogen
and progesterone receptor as well as human epidermal growth factor receptor 2. It is …

Abstract Purpose: BRCA1/2-mutated and some sporadic triple-negative breast cancers
(TNBC) have DNA repair defects and are sensitive to DNA-damaging therapeutics …

DNA repair competency is one determinant of sensitivity to certain chemotherapy drugs,
such as cisplatin. Cancer cells with intact DNA repair can avoid the accumulation of genome …

Purpose Cisplatin is a chemotherapeutic agent not used routinely for breast cancer
treatment. As a DNA cross-linking agent, cisplatin may be effective treatment for hereditary …

Recent gene expression profiling of breast cancer has identified specific subtypes with
clinical, biologic, and therapeutic implications. The basal-like group of tumors is …

Triple-negative breast cancers are defined by a lack of expression of oestrogen,
progesterone, and ERBB2 receptors. This subgroup accounts for 15% of all types of breast …

Sporadic basal-like cancers (BLC) are a distinct class of human breast cancers that are
phenotypically similar to BRCA1-associated cancers. Like BRCA1-deficient tumors, most …

Lack of molecular targets in estrogen receptor-negative (ER-negative) breast cancer is a
major therapeutic hurdle. We studied NF-κB activation in human breast tumors and in …

Adjuvant chemotherapy for breast cancer after surgery has effectively lowered metastatic
recurrence rates. However, a considerable proportion of women suffer recurrent cancer at …